NCCN tool will compare cancer drugs' cost-effectiveness

In October, the National Comprehensive Cancer Network plans to launch a tool to compare the cost-effectiveness of cancer treatments. The tool will incorporate metrics including cost, efficacy, safety, quality of evidence and consistency of evidence.

NCCN initially will evaluate treatments for multiple myeloma (MM) and chronic myelogenous leukemia (CML) and incorporate the tool into updated clinical practice guidelines for the indications. Spokesperson Katie Brown said the tool will allow physicians to "identify optimal treatment based on considerations that are of most value to a particular patient." ...